Ourofino (BSP:OFSA3) Accounts Payable & Accrued Expense: R$169 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:OFSA3 Ourofino SA BSP:OFSA3
81 GF Score
Price R$26.98
GF Value R$27.42
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Ourofino Accounts Payable & Accrued Expense?

Ourofino BSP:OFSA3 -1.68% 81 Accounts Payable & Accrued Expense is R$169 Mil as of Jun. 2026. GuruFocus rates BSP:OFSA3 with a GF Score™ of 81/100 and a GF Value™ of R$27.42 (Fairly Valued). The stock has 2 warning signs investors should review.

Ourofino's quarterly accounts payable & accrued expense increased from Dec. 2025 (R$167 Mil) to Mar. 2026 (R$196 Mil) but then declined from Mar. 2026 (R$196 Mil) to Jun. 2026 (R$169 Mil).

Ourofino's annual accounts payable & accrued expense increased from Dec. 2023 (R$86 Mil) to Dec. 2024 (R$161 Mil) and increased from Dec. 2024 (R$161 Mil) to Dec. 2025 (R$167 Mil).

Ourofino Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Ourofino's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ourofino Accounts Payable & Accrued Expense Chart

Ourofino Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 103.14 104.55 85.72 160.58 167.27

Ourofino Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 160.20 137.13 167.27 196.27 168.63
BSP:OFSA3
81GF Score
Ourofino SA BSP:OFSA3
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ourofino Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of R$169 Mil mean?
Ourofino (BSP:OFSA3) has a Accounts Payable & Accrued Expense of R$169 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Ourofino and its competitors.
Is Ourofino's Accounts Payable & Accrued Expense too high?
Ourofino's current Accounts Payable & Accrued Expense is R$169 Mil. Overall, Ourofino has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ourofino's Accounts Payable & Accrued Expense compare to ZTS and UTHR?
Ourofino's Accounts Payable & Accrued Expense of R$169 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Ourofino and its competitors. Ourofino's current Accounts Payable & Accrued Expense is R$169 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ourofino stock overvalued right now?
Based on GuruFocus' analysis, Ourofino (BSP:OFSA3) is currently considered Fairly Valued. The stock's GF Value™ is R$27.42, compared to a current price of R$26.98 — trading 1.6% below its estimated fair value. The current Accounts Payable & Accrued Expense is R$169 Mil. Ourofino's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Ourofino (BSP:OFSA3), the current Accounts Payable & Accrued Expense is R$169 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ourofino (BSP:OFSA3) Overvalued in 2026?

Based on GuruFocus' analysis, Ourofino stock appears to be undervalued. The current stock price of R$26.98 is trading 1.6% below its estimated GF Value™ of R$27.42. GuruFocus considers Ourofino to be Fairly Valued.

Key valuation signals for BSP:OFSA3:

  • Accounts Payable & Accrued Expense: R$169 Mil
  • GF Value™: R$27.42 vs. price of R$26.98 (1.6% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the BSP:OFSA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ourofino Business Description

Address Anhanguera Highway SP 330, Block C, 2nd floor, Km 298, Industrial District, Cravinhos, SP, BRA, 14140-000
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
81GF Score

Get the complete analysis for BSP:OFSA3

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$26.98
Price
R$27.42
GF Value